Cargando…

Improved generation of anti-tumor immunity by antigen dose limitation

BACKGROUND: The malignant cells of cutaneous T cell lymphoma (CTCL) display immunogenic peptides derived from the clonal T cell receptor (TCR) providing an attractive model for refinement of anti-tumor immunization methodology. To produce a clinically meaningful anti-tumor response, induction of cyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shofner, Joshua D, Vasquez, Juan G, Berger, Carole L, Edelson, Richard L
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800896/ https://www.ncbi.nlm.nih.gov/pubmed/17291350 http://dx.doi.org/10.1186/1476-8518-5-2

Ejemplares similares

Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading
por: Salskov-Iversen, Maria, et al.
Publicado: (2005)

Manipulation of habitat isolation and area implicates deterministic factors and limited neutrality in community assembly
por: Ord, Terry J., et al.
Publicado: (2017)

Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors
por: Jacqueline, Camille, et al.
Publicado: (2022)

Fusion Protein Vaccines Targeting Two Tumor Antigens Generate Synergistic Anti-Tumor Effects
por: Cheng, Wen-Fang, et al.
Publicado: (2013)

Enterococcus faecium secreted antigen A generates muropeptides to enhance host immunity and limit bacterial pathogenesis
por: Kim, Byungchul, et al.
Publicado: (2019)

Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice
por: Reeves, Patrick M., et al.
Publicado: (2017)

Siah2 control of T-regulatory cells limits anti-tumor immunity
por: Scortegagna, Marzia, et al.
Publicado: (2020)

Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells).
por: Perez, M. I., et al.
Publicado: (1989)

The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
por: Dovedi, Simon, et al.
Publicado: (2014)

Immune privilege of the CNS is not the consequence of limited antigen sampling
por: Harris, Melissa G., et al.
Publicado: (2014)

Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice
por: Reeves, Patrick M., et al.
Publicado: (2018)

Neuropilin-1 is a T cell memory checkpoint limiting long-term anti-tumor immunity
por: Liu, Chang, et al.
Publicado: (2020)

Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses
por: Silva, Mariana, et al.
Publicado: (2016)

In Vivo Visualization of Tumor Antigen-containing Microparticles Generated in Fluorescent-protein-elicited Immunity
por: Yang, Fei, et al.
Publicado: (2016)

B7H6-specific chimeric antigen receptors lead to tumor elimination and host anti-tumor immunity
por: Wu, Ming-Ru, et al.
Publicado: (2015)

Exponentially decreasing exposure of antigen generates anti-inflammatory T-cell responses
por: Esrafili, Arezoo, et al.
Publicado: (2023)

The Optimal Radiation Dose to Induce Robust Systemic Anti-Tumor Immunity
por: Poleszczuk, Jan, et al.
Publicado: (2018)

Core skin DC signatures control immune tolerance to skin cancer and limit anti-tumor immunity
por: Nirschl, Christopher, et al.
Publicado: (2015)

Talilmogene Iaherparepvec generates systemic T-cell-mediated anti-tumor immunity
por: Piasecki, Julia, et al.
Publicado: (2013)

MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response
por: Tagliamonte, Maria, et al.
Publicado: (2021)

Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination
por: Johnson, Laura E., et al.
Publicado: (2017)

The Immune Response to Melanoma Is Limited by Thymic Selection of Self-Antigens
por: Träger, Ulrike, et al.
Publicado: (2012)

Limitations of Anti-Angiogenic Treatment of Tumors
por: Ribatti, Domenico, et al.
Publicado: (2019)

Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity
por: Bikorimana, Jean-Pierre, et al.
Publicado: (2022)

Inhibition of tumor autophagy: a strategy to improve anti-tumor immunity?
por: Freeman, Andrew J., et al.
Publicado: (2020)

Next-Generation Immunotherapies to Improve Anticancer Immunity
por: Shi, Yaoyao, et al.
Publicado: (2021)

Single-Dose CpG Immunization Protects Against a Heterosubtypic Challenge and Generates Antigen-Specific Memory T Cells
por: Vogel, Alexander J., et al.
Publicado: (2015)

Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations
Publicado: (1981)

Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and anti-tumor efficacy
por: Cherry, Tiffani, et al.
Publicado: (2010)

Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor
por: Rajendrakumar, Santhosh Kalash, et al.
Publicado: (2018)

Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity
por: Sanchez, Sarah, et al.
Publicado: (2021)

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity
por: Huang, Jianmei, et al.
Publicado: (2022)

Parity improves anti-tumor immunity in breast cancer patients
por: Krause, Anna-Lena, et al.
Publicado: (2017)

Immunization of Mice with Anthrax Protective Antigen Limits Cardiotoxicity but Not Hepatotoxicity Following Lethal Toxin Challenge
por: Devera, T. Scott, et al.
Publicado: (2015)

Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation
por: Liu, Xiaojun, et al.
Publicado: (2017)

Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression
por: Nguyen, Kim Bich, et al.
Publicado: (2023)

Tumor Cell-Based Vaccine Generated With High Hydrostatic Pressure Synergizes With Radiotherapy by Generating a Favorable Anti-tumor Immune Microenvironment
por: Seitz, Christoph, et al.
Publicado: (2019)

Next-generation antigen-presenting cell immune therapeutics for gliomas
por: Lee-Chang, Catalina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3st4uuhptnbn4cimvk61e1f5vg